Skip to main content
Premium Trial:

Request an Annual Quote

Asuragen Raises $5M, Targeting $10M in Series C Round

NEW YORK (GenomeWeb News) – Molecular diagnostics shop Asuragen has raised $5 million toward a $10 million goal in its latest financing round.

In an e-mail to GenomeWeb Daily News, Asuragen Founder and CEO Matt Winkler confirmed the firm has closed the first $5 million of a $10 million Series C equity financing round, and added that the investment was made by an undisclosed "strategic venture investor."

"The proceeds of this round will accelerate the commercialization of our molecular diagnostics products and services," Winkler said, declining further comment.

Asuragen disclosed the financing in a document filed with the US Securities and Exchange Commission on Thursday.

Based in Austin, Texas, Asuragen was formed in 2006 and focuses on developing diagnostics for oncology and companion diagnostics using mRNA and microRNA technologies. According to its website, its product portfolio is comprised of multiplex oncology assays, RT-qPCR leukemia products, PCR assays for Fragile X testing, RNA stabilization technologies, and other things.

Asuragen had previously raised $18.5 million in a Series B round and $49 million in a Series A round.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.